Arrowhead to host webinar with interim Phase 1/2a ARO-MAPT data for Alzheimer’s

Arrowhead Pharmaceuticals (ARWR) plans to host a webinar featuring interim clinical data from a Phase 1/2a study of ARO-MAPT for the treatment of Alzheimer’s disease and other tauopathies.